Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Inclusion Criteria: * Age \> 18 years * Having undergone surgical excision of LM or LMM * Positive histological finding of LM or LMM (positive histology of primary excision) Exclusion Criteria: * History of allergic reaction to imiquimod or its excipients. * Pregnancy, breast-feeding or planned pregnancy during the study and women of child-bearing potential not using adequate contraception. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. \<1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner * History of malignant melanoma having metastasised or where metastasis could be expected * Other malignant tumours in the study treatment area (exception actinic keratosis (AK)) * Lack of ability or willingness to give informed consent * Lack of willingness to have personal study related data collected, archived or transmitted according to protocol * Anticipated non-availability for study visits/procedures